University of Maryland, Baltimore Technology Transfer
Generated by GPT-5-miniExpansion Funnel Raw 86 → Dedup 0 → NER 0 → Enqueued 0
| University of Maryland, Baltimore Technology Transfer | |
|---|---|
| Name | University of Maryland, Baltimore Technology Transfer |
| Established | 1990s |
| Location | Baltimore, Maryland |
| Parent | University of Maryland, Baltimore |
| Type | Technology transfer office |
University of Maryland, Baltimore Technology Transfer
The technology transfer office at the University of Maryland, Baltimore operates as the principal conduit between the research enterprises of University of Maryland, Baltimore School of Medicine, University of Maryland, Baltimore School of Pharmacy, University of Maryland Francis King Carey School of Law, University of Maryland School of Social Work, University of Maryland, Baltimore County collaborations and commercial entities such as GlaxoSmithKline, Pfizer, Merck & Co., Johnson & Johnson, and Bristol-Myers Squibb. It manages innovations arising from investigators affiliated with institutions including Maryland Institute for Clinical & Translational Research, Institute for Genome Sciences, Center for Vaccine Development, R Adams Cowley Shock Trauma Center, and Maryland Psychiatric Research Center. The office bridges academic assets and external stakeholders like National Institutes of Health, National Science Foundation, Food and Drug Administration, and Maryland Department of Commerce.
Overview
The unit facilitates protection, licensing, and commercialization of inventions originating from researchers linked to University of Maryland, Baltimore School of Dentistry, University of Maryland School of Nursing, University of Maryland, Baltimore School of Social Work, and centers such as University of Maryland Marlene and Stewart Greenebaum Cancer Center, Maryland Biotechnology Center, and Institute for Bioscience and Biotechnology Research. It supports translational pathways involving funders like Howard Hughes Medical Institute, Bill & Melinda Gates Foundation, Wellcome Trust, and corporate partners including AbbVie and Amgen. The office interacts with legal frameworks exemplified by Bayh–Dole Act and works alongside offices of similar scope such as Johns Hopkins Technology Ventures, MIT Technology Licensing Office, and Stanford Office of Technology Licensing.
Organizational Structure and Governance
Governance aligns with the University System of Maryland rules, reporting to executive leaders in entities such as University of Maryland Medical System, University System of Maryland Board of Regents, and executive officers comparable to university president roles like Jay A. Perman or counterparts at University of Maryland, College Park. Staff include licensing managers, patent counsel, business development officers, and compliance specialists who liaise with outside counsel firms and firms like Fish & Richardson, Cooley LLP, and WilmerHale. Committees draw members from deans of School of Medicine, chairs of departments like Department of Pharmacology, and external advisors from Maryland Tech Council, BioHealth Innovation, and investor networks including National Venture Capital Association.
Intellectual Property and Patent Management
IP management encompasses invention disclosure intake, patent prosecution, and portfolio strategy influenced by statutes and decisions involving Bayh–Dole Act, Diamond v. Chakrabarty-era precedent, and international regimes connected to World Intellectual Property Organization. The office coordinates patent filings with the United States Patent and Trademark Office, engages patent agents and firms, and manages freedom-to-operate analyses referencing cases such as Mayo Collaborative Services v. Prometheus Laboratories, Inc. and Alice Corp. v. CLS Bank International. IP types include biotechnology patents related to CRISPR-Cas9, diagnostics linked to polymerase chain reaction, medical devices akin to innovations at R Adams Cowley Shock Trauma Center, and software with interfaces for electronic health records employed across systems like Epic Systems Corporation.
Licensing, Commercialization, and Startup Support
Licensing strategies range from exclusive licenses with firms like MedImmune to non-exclusive arrangements with consortia modeled after Broad Institute collaborations. The office supports startup formation advising founders on term sheets similar to those used by Sequoia Capital and Andreessen Horowitz portfolio companies, connecting teams to incubators such as bwtech@UMBC, accelerators like Y Combinator, and regional investors including TEDCO and AngelList networks. Support services include material transfer agreements, sponsored research agreements influenced by templates from AUTM and deal structures seen in transactions involving Intrexon.
Research Collaborations and Industry Partnerships
Collaborations span clinical trials coordinated with ClinicalTrials.gov registrations, cooperative research with National Cancer Institute programs, and translational projects with pharmaceutical partners including Eli Lilly and AstraZeneca. Partnerships often involve memorandum of understanding frameworks used in alliances between Massachusetts Institute of Technology and industry, interinstitutional agreements with Johns Hopkins University, and consortium models exemplified by Accelerating Medicines Partnership. The office manages conflict of interest disclosures per standards echoed by Association of American Medical Colleges and grant management linked to National Institute of Allergy and Infectious Diseases awards.
Impact, Metrics, and Notable Technologies
Metrics track invention disclosures, patent filings, licenses executed, startup formation, and revenue streams measured against peers like Johns Hopkins Technology Ventures and University of Pennsylvania Center for Technology Transfer. Notable technologies have included vaccine candidates akin to those from Center for Vaccine Development, diagnostics comparable to advances from Institute for Genome Sciences, and drug candidates with preclinical origins similar to those at Molecular Foundry-affiliated labs. Economic impact analyses reference models used by Association of University Technology Managers and regional studies by Baltimore Development Corporation and Maryland Department of Commerce.
Policies, Compliance, and Ethical Considerations
Policy frameworks involve patent policies, export controls under International Traffic in Arms Regulations, human subjects protections aligned with Common Rule, and biosafety overseen by committees similar to Institutional Biosafety Committees that follow Centers for Disease Control and Prevention guidance. Compliance interfaces with conflict of interest policies influenced by National Institutes of Health mandates, data sharing norms seen in Human Genome Project principles, and ethical review processes akin to those administered by Institutional Review Boards.